BACKGROUND: Few studies have evaluated real-world treatment patterns and survival in follicular lymphoma (FL). This study evaluated these outcomes among newly diagnosed patients with FL in routine clinical care. PATIENTS AND METHODS: A retrospective study was conducted in newly diagnosed patients with FL from Humedica, a large United States electronic medical record database, from January 1, 2008 to July 31, 2015. Patients were followed from treatment initiation until death, loss to follow-up, or end of study (September 30, 2015). Treatment patterns were assessed in the follow-up period. Progression-free survival (PFS) and overall survival (OS) at 2 years were evaluated in the overall population using Kaplan-Meier analyses. OS was also compared between patients with and without evidence of disease progression within 2 years following first-line therapy (ie, early progressors vs. non-early progressors). RESULTS: A total of 1346 patients were included in the study, with most patients receiving rituximab-based regimens. Fewer early progressors received rituximab-based regimens. Across all lines, combination therapies predominated, particularly bendamustine + rituximab. Following first-line therapy, OS was 86.9% at 2 years, and median OS was not reached. Two-year PFS after first-line therapy was 64.6%, and median PFS was 48.1 months (95% confidence interval, 39.4-58.4 months). OS at 2 years was 76.8% among early progressors versus 90.4% among non-early progressors (P < .001); the median OS was not reached in both groups. CONCLUSION: In routine clinical practice, rituximab-based regimens predominated; however, utilization of these regimens differed among early and non-early progressors. The assessment of survival outcomes also highlights the negative impact of early progression on OS in the rituximab-era.
BACKGROUND: Few studies have evaluated real-world treatment patterns and survival in follicular lymphoma (FL). This study evaluated these outcomes among newly diagnosed patients with FL in routine clinical care. PATIENTS AND METHODS: A retrospective study was conducted in newly diagnosed patients with FL from Humedica, a large United States electronic medical record database, from January 1, 2008 to July 31, 2015. Patients were followed from treatment initiation until death, loss to follow-up, or end of study (September 30, 2015). Treatment patterns were assessed in the follow-up period. Progression-free survival (PFS) and overall survival (OS) at 2 years were evaluated in the overall population using Kaplan-Meier analyses. OS was also compared between patients with and without evidence of disease progression within 2 years following first-line therapy (ie, early progressors vs. non-early progressors). RESULTS: A total of 1346 patients were included in the study, with most patients receiving rituximab-based regimens. Fewer early progressors received rituximab-based regimens. Across all lines, combination therapies predominated, particularly bendamustine + rituximab. Following first-line therapy, OS was 86.9% at 2 years, and median OS was not reached. Two-year PFS after first-line therapy was 64.6%, and median PFS was 48.1 months (95% confidence interval, 39.4-58.4 months). OS at 2 years was 76.8% among early progressors versus 90.4% among non-early progressors (P < .001); the median OS was not reached in both groups. CONCLUSION: In routine clinical practice, rituximab-based regimens predominated; however, utilization of these regimens differed among early and non-early progressors. The assessment of survival outcomes also highlights the negative impact of early progression on OS in the rituximab-era.
Authors: Nathan H Fowler; Guifang Chen; Stephen Lim; Stephanie Manson; Qiufei Ma; Frank Yunfeng Li Journal: J Health Econ Outcomes Res Date: 2020-09-04
Authors: Aino Rajamäki; Mika Hujo; Reijo Sund; Roosa E I Prusila; Milla E L Kuusisto; Hanne Kuitunen; Esa Jantunen; Santiago Mercadal; Marc Sorigue; Juan-Manuel Sancho; Kaisa Sunela; Outi Kuittinen Journal: Cancer Date: 2022-04-13 Impact factor: 6.921
Authors: Nathan H Fowler; Felipe Samaniego; Wojciech Jurczak; Nilanjan Ghosh; Enrico Derenzini; James A Reeves; Wanda Knopińska-Posłuszny; Chan Y Cheah; Tycel Phillips; Ewa Lech-Maranda; Bruce D Cheson; Paolo F Caimi; Sebastian Grosicki; Lori A Leslie; Julio C Chavez; Gustavo Fonseca; Sunil Babu; Daniel J Hodson; Spencer H Shao; John M Burke; Jeff P Sharman; Jennie Y Law; John M Pagel; Hari P Miskin; Peter Sportelli; Owen A O'Connor; Michael S Weiss; Pier Luigi Zinzani Journal: J Clin Oncol Date: 2021-03-08 Impact factor: 44.544
Authors: Ahmad S Halwani; Kelli M Rasmussen; Vikas Patil; Deborah Morreall; Catherine Li; Christina Yong; Zachary Burningham; Keith Dawson; Anthony Masaquel; Kevin Henderson; Elisha DeLong-Sieg; Brian C Sauer Journal: Cancer Med Date: 2020-08-28 Impact factor: 4.452